Hemodynamic Effects of 8-Day DL-028 and Octreotide Administration in Rats with Portal Hypertension

Background: DL-028 (chemical name: 3-[[4-(2-methoxyphenyl)piperazin-1-yl]methyl]-2,3-dihydroimidazo[1,2-c]quinazolin-5(6H

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Scandinavian journal of gastroenterology 1998, Vol.33 (12), p.1303-1309
Hauptverfasser:	HUANG, Y.-T, WU, H.-L, CHERN, J.-W, LIN, H.-C, HONG, C.-Y
Format:	Artikel
Sprache:	eng
Schlagworte:	Adrenergic alpha-Antagonists - administration & dosage Adrenergic alpha-Antagonists - pharmacology Animals Antihypertensive agents Biological and medical sciences Cardiovascular system Drug Administration Schedule Drug Therapy, Combination Hemodynamics - drug effects Hemostatics - administration & dosage Hemostatics - pharmacology Hypertension, Portal - drug therapy Male Medical sciences Octreotide - administration & dosage Octreotide - pharmacology Pharmacology. Drug treatments Quinazolines - administration & dosage Quinazolines - pharmacology Rats Rats, Sprague-Dawley
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Background: DL-028 (chemical name: 3-[[4-(2-methoxyphenyl)piperazin-1-yl]methyl]-2,3-dihydroimidazo[1,2-c]quinazolin-5(6H
ISSN:	0036-5521 1502-7708
DOI:	10.1080/00365529850172403